Jan. 6, 2000
Contact: Carey Hoffman
Cincinnati -- UC started the new year by moving up in two major national ranking reports. The first directly measures the productivity of university researchers. The other measures the impact of that research in terms of patent and licensing income.
For the first time, the National Science Foundation now lists UC in its Top 50 for research and development (R&D) expenditures, just two notches below Virginia Tech and seven notches away from the prestigious California Institute of Technology.
"This puts us in very good company," said Howard Jackson, UC's vice president for research and university dean for advanced studies. "We're doing well, showing improvement in a very competitive environment."
UC has risen from No. 62 on the list three years ago to the No. 50 spot. R&D expenditures during that time have grown from $127.7 million to $159.69 million.
In addition to the No. 50 research ranking, UC also moved up to No. 31 in the latest rankings released by the Association of University Technology Managers. The report measured income from the 1998 fiscal year. UC earned $3.27 million in fiscal 1998, up from $2.66 million the previous year.
UC's ranking was three spots better than a year ago and again No. 1 among all Ohio schools and among the best in the region, ahead of other major research institutions such as Ohio State and Purdue. "I was pleased to see us move up a couple of notches," said Norm Pollack, director of UC's Office of Intellectual Property. "We were helped by some of the developments we've seen in the pharmaceutical industry."
The top royalty producers continued to be Cardiolite® and Myoview®, a pair of popular heart imaging agents. With their help and the expected growth elsewhere, Pollack expects UC's earnings in fiscal year 1999 to top $4 million.
National growth for universities in royalty income continued its recent exponential pace, jumping from $446 million in fiscal year 1997 to $614 million in fiscal year 1998.
"The biggest problem in the past was that these technologies from universities were usually very early in their development, and it takes a lot of steps and money and time to get them from the lab to the point where they are ready to go to market," Pollack said. "So we're seeing more and more licensing to start-up companies, who are able to get venture funds."
Pollack is still hopeful other projects that are tied to UC will make a big impact in the coming years.
Among the products that look promising are a bone cancer drug being marketed in Europe by Mallinkrodt, an anti-corrosion chemical in development with Brent International and a cellular imaging process by Intracellular Imaging Inc.
Two other start-up companies that originated at the UC Medical Center that could
be promising are CardioEnergetics, which is developing heart-assist devices, and
Cutanogen, which is developing a skin replacement technology for burn victims.